TIDMVAL

RNS Number : 2232E

ValiRx PLC

06 July 2021

6 July 2021

ValiRx PLC

("ValiRx", the "Company" or the "Group")

Patent Status Update

London, UK - ValiRx plc ("ValiRx", AIM:VAL), a clinical stage drug development company, is pleased to report that its patent portfolio continued to build in the first half of 2021.

2021 patent advances

 
 Project   Patent Family       Patent Granted   Date Granted   Impact 
 VAL201    WO/2014/177868      EP2991662        June 2021      Extends protection 
                                                                for the use of VAL201 
                                                                into metastatic cancer, 
                                                                grant allowance announced 
                                                                January 2021 
            Use of the          (European) 
             peptide against 
             metastases 
          ------------------  ---------------  -------------  ------------------------------ 
 VAL301    WO/2013/064830      IL232239         June 2021      Extends granted patent 
                                                                coverage into Israel 
                                                                for the use in the 
                                                                treatment of endometriosis, 
                                                                as well as other 
                                                                non-cancerous hormone-driven 
                                                                conditions 
            Use of the          (Israel) 
             peptide against 
             non-cancerous 
             proliferative 
             conditions 
          ------------------  ---------------  -------------  ------------------------------ 
 VAL401    WO/2015/169971      CN106456644      June 2021      The second Chinese 
                                                                patent granted for 
                                                                VAL401, extends the 
                                                                use into additional 
                                                                adenocarcinoma types 
                                (China) 
          ------------------  ---------------  -------------  ------------------------------

The full patent portfolio for each project can be found on the project pages of the Company's website: https://www.valirx.com/our-pipeline

Dr Suzy Dilly, Chief Executive Officer commented: "I'm pleased to provide this periodic report of progress throughout our patent portfolio. Expanding geographical and scientific protection for these programmes provides a strong commercial background to promote to potential partners. This incremental increase in protection of our intellectual property estate provides foundation for company valuation growth."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.

Ends

For further information please contact:

 
 ValiRx plc                                        Tel: +44 (0) 2476 796496 
                                                    www.valirx.com 
 Suzanne Dilly, CEO                                Suzanne.Dilly@valirx.com 
  Cairn Financial Advisers LLP (Nominated           Tel: +44 (0) 20 7213 
   Adviser)                                          0880 
   Liam Murray / Jo Turner / Ludovico Lazzaretti 
  Peterhouse Capital Limited (Sole Broker)          Tel: +44 (0) 20 7469 
   Duncan Vasey / Lucy Williams / Eran Zucker        0930 
  Optimum Strategic Communications                  Tel: +44 (0) 20 8148 
   Supriya Mathur/ Shabnam Bashir                    3040 
                                                     valirx@optimumcomms.com

About ValiRx plc

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary

companies for further clinical development and commercialisation.   https://www.valirx.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSSFFIIEFSESW

(END) Dow Jones Newswires

July 06, 2021 02:00 ET (06:00 GMT)

Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Valirx.
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Valirx.